Chantest
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Seed | ||
$54.0m Valuation: $54.0m | Acquisition | ||
Total Funding | - |
Recent News about Chantest
EditChantest is a specialized preclinical research service provider focusing on drug discovery and safety assessment for the pharmaceutical and biotech industries. The company operates in the life sciences sector, offering a range of services that include ion channel screening, cardiac safety testing, and custom assay development. Chantest serves clients ranging from small biotech startups to large pharmaceutical companies, helping them to accelerate their drug development processes and ensure regulatory compliance. The business model is service-based, generating revenue through contracts and partnerships with its clients. By providing high-quality, reliable data, Chantest enables its clients to make informed decisions in their drug development pipelines, ultimately contributing to the advancement of medical science.
Keywords: preclinical research, drug discovery, safety assessment, ion channel screening, cardiac safety, custom assays, biotech, pharmaceutical, regulatory compliance, life sciences.